In Vitro Human Monoamine Oxidase Inhibition and Human Dopamine D4 Receptor Antagonist Effect of Natural Flavonoids for Neuroprotection
-
Published:2023-11-01
Issue:21
Volume:24
Page:15859
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Paudel Pradeep1ORCID, Choi Jae Sue2ORCID, Prajapati Ritu2ORCID, Seong Su Hui23, Park Se Eun2, Kang Woo-Chang4, Ryu Jong-Hoon4, Jung Hyun Ah5ORCID
Affiliation:
1. Invasive Insect Biocontrol and Behavior Laboratory, Beltsville Agricultural Research Center-West, USDA-ARS, Beltsville, MD 20705, USA 2. Department of Food and Life Science, Pukyong National University, Busan 48513, Republic of Korea 3. Natural Products Research Division, Honam National Institute of Biological Resource, Mokpo 58762, Republic of Korea 4. Department of Oriental Pharmaceutical Science, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea 5. Department of Food Science and Human Nutrition, Jeonbuk National University, Jeonju 54896, Republic of Korea
Abstract
Natural flavone and isoflavone analogs such as 3′,4′,7-trihydroxyflavone (1), 3′,4′,7-trihydroxyisoflavone (2), and calycosin (3) possess significant neuroprotective activity in Alzheimer’s and Parkinson’s disease. This study highlights the in vitro human monoamine oxidase (hMAO) inhibitory potential and functional effect of those natural flavonoids at dopamine and serotonin receptors for their possible role in neuroprotection. In vitro hMAO inhibition and enzyme kinetics studies were performed using a chemiluminescent assay. The functional effect of three natural flavonoids on dopamine and serotonin receptors was tested via cell-based functional assays followed by a molecular docking simulation to predict interactions between a compound and the binding site of the target protein. A forced swimming test was performed in the male C57BL/6 mouse model. Results of in vitro chemiluminescent assays and enzyme kinetics depicted 1 as a competitive inhibitor of hMAO-A with promising potency (IC50 value: 7.57 ± 0.14 μM) and 3 as a competitive inhibitor of hMAO-B with an IC50 value of 7.19 ± 0.32 μM. Likewise, GPCR functional assays in transfected cells showed 1 as a good hD4R antagonist. In docking analysis, these active flavonoids interacted with a determinant-interacting residue via hydrophilic and hydrophobic interactions, with low docking scores comparable to reference ligands. The post-oral administration of 1 to male C57BL/6 mice did not reduce the immobility time in the forced swimming test. The results of this study suggest that 1 and 3 may serve as effective regulators of the aminergic system via hMAO inhibition and the hD4R antagonist effect, respectively, for neuroprotection. The route of administration should be considered.
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference88 articles.
1. Association of screen time and depression in adolescence;Boers;JAMA Pediatr.,2019 2. Davidson, M., Rashidi, N., Nurgali, K., and Apostolopoulos, V. (2022). The role of tryptophan metabolites in neuropsychiatric disorders. Int. J. Mol. Sci., 23. 3. Tryptophan in health and disease;Comai;Adv. Clin. Chem.,2020 4. Tryptophan metabolism: Mechanism-oriented therapy for neurological and psychiatric disorders;Li;Front. Immunol.,2022 5. Polyák, H., Galla, Z., Nánási, N., Cseh, E.K., Rajda, C., Veres, G., Spekker, E., Szabó, Á., Klivényi, P., and Tanaka, M. (2023). The tryptophan-kynurenine metabolic system is suppressed in cuprizone-induced model of demyelination simulating progressive multiple sclerosis. Biomedicines, 11.
|
|